TickerFacts.

Dyadic International Inc (DYAI): Revenue

Annual figures by period end, from SEC filings.

$3.09M
Year ended 2025-12-31
$3.80M
Trailing 12 months to 2026-06-30
+1.8%
3-year compound annual growth
+14.0%
5-year compound annual growth
$3.50M2017-12-31: $758.4K2018-12-31: $1.30M2019-12-31: $1.68M2020-12-31: $1.60M2021-12-31: $2.40M2022-12-31: $2.93M2023-12-31: $2.90M2024-12-31: $3.50M2025-12-31: $3.09M$3.09M
2017-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$3.09M-11.6%2026-03-25, From 2025-01-01
2024-12-31$3.50M+20.6%2026-03-25, From 2024-01-01
2023-12-31$2.90M-1.1%2025-03-26, From 2023-01-01
2022-12-31$2.93M+21.9%2024-03-28, From 2022-01-01
2021-12-31$2.40M+50.1%2023-03-29, From 2021-01-01
2020-12-31$1.60M-4.7%2022-03-29, From 2020-01-01
2019-12-31$1.68M+29.8%2021-03-30, From 2019-01-01
2018-12-31$1.30M+70.8%2020-03-30, From 2018-01-01
2017-12-31$758.4Kn/a2019-03-27, From 2017-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Dyadic International Inc (DYAI)2025-12-31$3.09M-11.6%
Surrozen, Inc. (SRZN)2025-12-31$3.48M-67.4%
CRISPR Therapeutics AG (CRSP)2025-12-31$3.51M-90.6%
CG Oncology, Inc. (CGON)2025-12-31$4.04M+254.7%
Aligos Therapeutics, Inc. (ALGS)2025-12-31$2.19M-39.5%
Ocugen, Inc. (OCGN)2025-12-31$4.41M+8.8%
Prime Medicine, Inc. (PRME)2025-12-31$4.63M+55.3%
Humacyte, Inc. (HUMA)2025-12-31$2.04Mn/a
Zeo ScientifiX, Inc. (ZEOX)2025-10-31$5.20M+12.5%

Compare DYAI, SRZN, CRSP, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗